Medtronic Raises 2027 Forecasts Amid Surge in Heart Device Demand

Medtronic has adjusted its fiscal 2027 revenue and profit forecasts upwards, citing a robust demand for its heart devices used in complex cardiovascular procedures. The medical technology giant now anticipates annual organic revenue growth between 7.25% and 7.75%, an increase from the previous estimate of 6.75% to 7.25%.

Strategic Investments and Acquisitions

A key factor in Medtronic's optimistic outlook is its recent strategic investments. The company announced an $80 million investment in Pi-Cardia, a heart-valve repair device maker, with an option to purchase the company for $210 million. Additionally, Medtronic invested $700 million in Cornerstone Robotics, securing rights to distribute a robotic surgical device in several international markets.

CEO Geoff Martha emphasized the significance of these investments, stating that they align with Medtronic's focus on high-growth segments within the medtech industry. "We are prioritizing segments with large patient pools and significant growth potential," Martha noted.

Financial Performance and Market Dynamics

Medtronic's cardiovascular segment reported a 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was largely driven by its pulsed field ablation portfolio, which experienced an 88% surge due to its effectiveness in treating irregular heart rhythms.

The company also reported an adjusted quarterly per share profit of $1.45, surpassing analyst expectations of $1.39, on revenue of $9.76 billion, which also exceeded the projected $9.55 billion.

Medtronic's CFO Thierry Pieton highlighted that the company received tariff refunds that nearly covered its duties for the quarter, although future refunds have not been factored into the updated forecast.

Expanding Global Footprint

Medtronic's investment in Cornerstone Robotics underscores its commitment to expanding its global presence, particularly in emerging markets where soft tissue robotic surgery penetration remains below 1%. Martha described the Cornerstone Sentire system as complementary to Medtronic's Hugo device, enhancing the company's surgical robotics offerings.

These initiatives reflect Medtronic's broader strategy to leverage its financial strength and industry expertise to capture new opportunities in the evolving healthcare landscape. The increased adoption of advanced medical technologies and the rising demand for surgical procedures are expected to continue driving growth for the company.